Dergiler / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 2

IndiaUltrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent:study of clinical and safety profiles among real-world patientsIntroduction

Sayfa
111–119
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Definite and probable ST were observed in 8 (1.1%) and 9 (1.3%) patients, respectively.Conclusion: Ultralong (≥40 mm), ultrathin (60 μm) Supralimus Grace stent can be safely implanted in vessels having long and multiple lesions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Although thin-strut drug-eluting stents (DES) with a more flexible design are easily obtainable, data regarding using ultralong DES (≥40 mm) for long coronary lesions are limited in the literature.
📊
Temel Bulgular & Veri:Therefore, the current study assessed the safety and efficacy of an ultralong (≥40 mm) and ultrathin (60 μm) biodegradable polymer-coated sirolimus-eluting stent (SES), Supralimus Grace, with a unique Long Dual Z-link (LDZ-link) design (Sahajanand Medical Technologies Pvt.
💡
Sonuç & Katkı:Definite and probable ST were observed in 8 (1.1%) and 9 (1.3%) patients, respectively.Conclusion: Ultralong (≥40 mm), ultrathin (60 μm) Supralimus Grace stent can be safely implanted in vessels having long and multiple lesions.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Although thin-strut drug-eluting stents (DES) with a more flexible design are easily obtainable, data regarding using ultralong DES (≥40 mm) for long coronary lesions are limited in the literature. Therefore, the current study assessed the safety and efficacy of an ultralong (≥40 mm) and ultrathin (60 μm) biodegradable polymer-coated sirolimus-eluting stent (SES), Supralimus Grace, with a unique Long Dual Z-link (LDZ-link) design (Sahajanand Medical Technologies Pvt. Ltd., Surat, India) in real-world patients with long coronary lesions.Methods: The assigned stents were implanted in 684 patients. The primary endpoint was target lesion failure (TLF), which is a composite of cardiovascular death, target vessel myocardial infarction (MI), and target lesion revascularization (TLR), whereas periprocedural secondary endpoints included device failure (failure of stent delivery, change of stent, and stent fracture) and patient-oriented composite endpoint (POCE), which is a composite of all deaths, any MI, and any revascularization, and stent thrombosis (ST). These outcomes were analyzed at one-year follow-up and during the procedure.Results: The patients’ mean age was 52.7±15.9 years; 537 (78.5%) were males. 626 (91.5%) patients suffered from acute coronary syndrome and 58 (8.5%) patients from chronic coronary syndrome (CSS). 989 lesions were removed. The mean numbers of lesions and stents implanted per patient were 1.3±0.2 mm and 1.4±0.3 mm, respectively. TLF occurred in 42 (6.1%) as a result of cardiac death, target vessel MI, and TLR in 9 (1.3%), 20 (2.9%), and 13 (1.9%) patients, respectively. POCE was observed in 131 patients (19.1%) at one-year follow-up, mainly in 63 (9.2%) patients because of any revascularization. Stent failure was seen in 21 patients (3.1%) as a result of delivery failure (2.2%), edge dissection (0.8%), and fracture (0.1%). Definite and probable ST were observed in 8 (1.1%) and 9 (1.3%) patients, respectively.Conclusion: Ultralong (≥40 mm), ultrathin (60 μm) Supralimus Grace stent can be safely implanted in vessels having long and multiple lesions.

🔖

Bu Makaleye Atıf Yap

SİNHA, S. K., AGGARWAL, P., PANDEY, U., RAZİ, M., KUMAR, A., KRİSHNA, V. (2021). IndiaUltrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent:study of clinical and safety profiles among real-world patientsIntroduction. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 2, 111–119. https://ajindex.com/articles/403138

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Schunkert H, Harrell L, Palacios IF. Implications of small referencevessel diameter in patients undergoing percutaneous coronary re-vascularization. J Am Coll Cardiol 1999
  2. 40–8.2 8.2.van der Heijden LC, Kok MM, Danse PW, Schramm AR, HartmannM, Löwik MM, et al. Small-vessel treatment with contemporarynewer-generation drug-eluting coronary stents in all-comers: In-sights from 2-year DUTCH PEERS (TWENTE II) randomized trial. Am Heart J 2016
  3. 28–35.3. Wöhrle J, Markovic S, Rottbauer W, Muramatsu T, Kadota K, Vázquez-González N, et al. Bioresorbable polymer sirolimus-eluting coronarystent compared with permanent polymer everolimus-eluting coro-nary stent implantation for treatment of small vessel coronary arterydisease: CENTURY II trial. EuroIntervention 2016
  4. e167–74. 4.Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E,et al. Impact of lesion length and vessel size on clinical outcomesafter percutaneous coronary intervention with everolimus- versuspaclitaxel-eluting stents pooled analysis from the SPIRIT (ClinicalEvaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-tem) and COMPARE (Second-generation everolimus-eluting andpaclitaxel-eluting stents in real-life practice) Randomized Trials.JACC Cardiovasc Interv 2011
  5. 1209–15. 5.Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, et al.Vessel size and outcome after coronary drug-eluting stent place-ment: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006
  6. 1304–9. 6.Amirzadegan A, Hasanabadi M, Saadatagah S, Afarideh M, OmidiN, Aghajani H, et al. Single Long Stents versus Overlapping Multiple Stents in the Management of Very Long Coronary Lesions: Compar-isons of Procedures and Clinical Outcomes. J Tehran Heart Cent2019
  7. 94–102. 7. Stefanini GG, Taniwaki M, Windecker S. Coronary stents: novel de-velopments. Heart 2014
  8. 1051–61. 8.Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Mass-berg S, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percuta-neous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS random-ized trials. Eur Heart J 2012
  9. 1214–22. 9.Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, etal. Abluminal biodegradable polymer biolimus-eluting stent versusdurable polymer everolimus-eluting stent (COMPARE II): a ran-domised,